Ascendis Pharma A/S (ASND)

Market Cap	13.07B
Revenue (ttm)	998.25M +134.8%
Net Income	571.81M
EPS	9.26
Shares Out	62.11M
PE Ratio	22.72
Forward PE	48.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	592,713
Open	220.51
Previous Close	218.84
Day's Range	209.56 - 222.55
52-Week Range	209.56 - 250.27
Beta	0.49
Analysts	Strong Buy
Price Target	295.11 (+40.23%)
Earnings Date	May 7, 2026

About ASND

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 1,189
• Stock Exchange: NASDAQ
• Ticker Symbol: ASND
• Website: https://ascendispharma.com

Financial Performance

In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.

Financial numbers in EUR

Analyst Summary

According to 17 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $295.11, which is an increase of 40.23% from the latest price.

Price Target

$295.11

(40.23% upside)

Analyst Consensus: Strong Buy